Acadia Healthcare Company Inc (NASDAQ:ACHC) CEO Debra K. Osteen Acquires 20,000 Shares
Acadia Healthcare Company Inc (NASDAQ:ACHC) CEO Debra K. Osteen purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was acquired at an average cost of $26.53 per share, with a total value of $530,600.00. Following the purchase, the chief executive officer now directly owns 117,178 shares of the company’s stock, valued at $3,108,732.34. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Acadia Healthcare stock opened at $31.94 on Thursday. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $2.56 billion, a P/E ratio of 14.26, a P/E/G ratio of 1.28 and a beta of 0.71. The business has a fifty day simple moving average of $28.50 and a two-hundred day simple moving average of $30.94. Acadia Healthcare Company Inc has a 12 month low of $24.27 and a 12 month high of $45.35.
Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.59 by $0.02. The business had revenue of $789.00 million during the quarter, compared to analyst estimates of $795.31 million. Acadia Healthcare had a positive return on equity of 7.20% and a negative net margin of 6.80%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 earnings per share. Analysts predict that Acadia Healthcare Company Inc will post 2.14 earnings per share for the current year.
A number of analysts recently commented on the company. Raymond James lowered Acadia Healthcare from a “strong-buy” rating to an “outperform” rating and set a $45.00 price target for the company. in a research note on Wednesday, July 31st. BidaskClub raised Acadia Healthcare from a “strong sell” rating to a “sell” rating in a research note on Wednesday. UBS Group dropped their price target on Acadia Healthcare from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Friday, September 6th. Mizuho set a $30.00 price target on Acadia Healthcare and gave the stock a “hold” rating in a research note on Friday, May 31st. Finally, Zacks Investment Research lowered Acadia Healthcare from a “hold” rating to a “sell” rating and set a $31.00 price objective for the company. in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. Acadia Healthcare presently has an average rating of “Hold” and a consensus price target of $36.00.
About Acadia Healthcare
Acadia Healthcare Company, Inc develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States, the United Kingdom, and Puerto Rico.
Featured Story: What is Compound Interest?
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.